Australian industry welcomes price study
The Australian Pharmaceutical Manufacturers Association has welcomed thepublication of an eight-country price comparison study by the Productivity Commission, which shows that manufacturers' prices for pharmaceuticals in Australia are lower than in the USA, Canada, the UK and Sweden.
However, APMA president Alan Evans also noted his concern that the International Pharmaceutical Price Differences study shows Australian prices to be comparable to those in New Zealand.
"The focus in New Zealand has been on price, which has had a devastating effect on the industry as a result of reduced investment," said Mr Evans, adding that: "access to medicines for patients in New Zealand is neither fair nor equitable - neither do they have access to the latest and best medicines."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze